Orion Oyj (ORINF)

40.29 0.00 (0.00%) At close: 12:43PM EDT

Orion Oyj

Orionintie 1A
Espoo 02200
Finland
358 10 4261
https://www.orion.fi

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full-time employees: 3,381

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Timo Lappalainen	CEO, Pres & Chairman of the Exec. Management Board	1.8M	N/A	1962
Mr. Jari Karlson M.Sc., M.Sc. (Econ.)	CFO, Sr. VP of Animal Health & Member of the Exec. Management Board	N/A	N/A	1961
Mr. Olli Huotari Ll.M.	Sr. VP of Corp. Functions, Gen. Counsel, Sec. & Member of Exec. Management Board	N/A	N/A	1966
Ms. Satu Ahomäki M.Sc. (Econ.)	Sr. VP of Commercial Operations & Member of the Exe. Mgmt. Board	N/A	N/A	1966
Dr. Liisa Hurme	Sr. VP of Global Operations & Member of the Exec. Management Board	N/A	N/A	1967
Ms. Virve Laitinen M.Sc. (Tech.), MBA	Sr. VP of Specialty Products & Member of Exec. Management Board	N/A	N/A	1972
Prof. Outi Vaarala M.D., Ph.D.	Sr. VP for R&D and Member of Exec. Management Board	N/A	N/A	1962
Mr. Tuukka Hirvonen M.Sc.(Soc.)	Investor Relations & Financial Communications Officer	N/A	N/A	N/A
Ms. Terhi Ormio	VP of Communications	N/A	N/A	N/A
Prof. Heikki Joensuu M.D., Ph.D.	R&D Global Head of Therapy Area Oncology	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Corporate governance

Orion Oyj’s ISS governance QualityScore as of 1 July 2022 is 4. The pillar scores are Audit: 3; Board: 1; Shareholder rights: 10; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.